Interim Data From Imago BioSciences’ Phase 2b Study of Bomedemstat (IMG-7289) for Treatment of Myelofibrosis to Be Presented at 62nd American Society of Hematology Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Imago BioSciences, Inc., (“Imago”) a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that interim data from its ongoing Phase 2b study evaluating bomedemstat (IMG-7289) for the treatment of myelofibrosis will be presented in an oral session during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually Dec. 5-8, 2020. An abstract containing preliminary findings will be published in the meeting program on Nov. 5, with updated findings presented during the oral session.

Oral Presentation Information:

  • Session: 634 - Myeloproliferative Syndromes: Clinical: New Therapies and JAKi-based Combinations for Myelofibrosis
  • Title: A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
  • Presenter: Kristen M. Pettit, M.D., Assistant Professor of Medicine at the University of Michigan, Rogel Cancer Center, Ann Arbor, Michigan
  • Presentation Date: 7:30 am ET on Saturday, Dec. 5, 2020

About Bomedemstat (IMG-7289)

Bomedemstat is being evaluated in an open-label Phase 2 clinical trial for the treatment of advanced myelofibrosis (MF), a bone marrow cancer that interferes with the production of blood cells. MF patients who are resistant to, intolerant of, or ineligible for a Janus Kinase (JAK) inhibitor are eligible for the study of bomedemstat as monotherapy. The endpoints include spleen volume reduction and symptom improvement at 12 and 24 weeks of treatment. Preliminary results were most recently presented at the 2020 European Hematology Association. In addition to the MF study, bomedemstat is also being evaluated for the treatment of essential thrombocythemia and polycythemia vera.

Bomedemstat is an orally available small molecule discovered and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, bomedemstat demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other chemotherapeutic agents. Bomedemstat is an investigational agent currently being evaluated in multiple ongoing clinical trials (ClinicalTrials.gov Identifier: NCT03136185, NCT04262141, NCT04254978 and NCT04081220). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of myelofibrosis and essential thrombocythemia, Orphan Drug Designation for treatment of acute myeloid leukemia and PRIME designation by the European Medicines Agency for the treatment of MF.

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of hematologic disorders targeting epigenetic enzymes. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell differentiation. Imago is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms. Imago BioSciences is backed by leading strategic and venture investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

Contacts

Steve Kunszabo
Canale Communications
steve@canalecomm.com
(619) 849-5388

 

 
 

Source: Imago BioSciences, Inc.

Back to news